Literature DB >> 19075275

Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma.

Eiji Kikuchi1, Vitaly Margulis, Pierre I Karakiewicz, Marco Roscigno, Shuji Mikami, Yair Lotan, Mesut Remzi, Christian Bolenz, Cord Langner, Alon Weizer, Francesco Montorsi, Karim Bensalah, Theresa M Koppie, Mario I Fernández, Jay D Raman, Wassim Kassouf, Christopher G Wood, Nazareno Suardi, Mototsugu Oya, Shahrokh F Shariat.   

Abstract

PURPOSE: To assess the association of lymphovascular invasion (LVI) with cancer recurrence and survival in a large international series of patients treated with radical nephroureterectomy (RNU) for upper urinary tract urothelial carcinoma (UTUC). PATIENTS AND METHODS: Data were collected on 1,453 patients treated with RNU at 13 academic centers and combined into a relational database. Pathologic slides were rereviewed by genitourinary pathologists according to strict criteria. LVI was defined as presence of tumor cells within an endothelium-lined space.
RESULTS: LVI was observed in 349 patients (24%). Proportion of LVI increased with advancing tumor stage, high tumor grade, presence of tumor necrosis, sessile tumor architecture, and presence of lymph node metastasis (all P < .001). LVI was an independent predictor of disease recurrence and survival (P < .001 for both). Addition of LVI to the base model (comprising pathologic stage, grade, and lymph node status) marginally improved its predictive accuracy for both disease recurrence and survival (1.1%, P = .03; and 1.7%, P < .001, respectively). In patients with negative lymph nodes and those in whom a lymphadenectomy was not performed (n = 1,313), addition of LVI to the base model improved the predictive accuracy of the base model for both disease recurrence and survival by 3% (P < .001 for both). In contrast, LVI was not associated with disease recurrence or survival in node-positive patients (n = 140).
CONCLUSION: LVI was an independent predictor of clinical outcomes in nonmetastatic patients who underwent RNU for UTUC. Assessment of LVI may help identify patients who could benefit from multimodal therapy after RNU. After confirmation, LVI should be included in staging of UTUC.

Entities:  

Mesh:

Year:  2008        PMID: 19075275      PMCID: PMC2737380          DOI: 10.1200/JCO.2008.17.2361

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  27 in total

1.  Upper tract urothelial neoplasms: incidence and survival during the last 2 decades.

Authors:  J J Munoz; L M Ellison
Journal:  J Urol       Date:  2000-11       Impact factor: 7.450

2.  EAU guidelines on diagnosis and treatment of upper urinary tract transitional cell carcinoma.

Authors:  W Oosterlinck; E Solsona; A P M van der Meijden; R Sylvester; A Böhle; E Rintala; B Lobel
Journal:  Eur Urol       Date:  2004-08       Impact factor: 20.096

3.  Evaluating the yield of medical tests.

Authors:  F E Harrell; R M Califf; D B Pryor; K L Lee; R A Rosati
Journal:  JAMA       Date:  1982-05-14       Impact factor: 56.272

4.  Simplified staging for hepatocellular carcinoma.

Authors:  Jean-Nicolas Vauthey; Gregory Y Lauwers; Nestor F Esnaola; Kim-Anh Do; Jacques Belghiti; Nadeem Mirza; Steven A Curley; Lee M Ellis; Jean-Marc Regimbeau; Asif Rashid; Karen R Cleary; David M Nagorney
Journal:  J Clin Oncol       Date:  2002-03-15       Impact factor: 44.544

5.  Lymphatic metastasis in the absence of functional intratumor lymphatics.

Authors:  Timothy P Padera; Ananth Kadambi; Emmanuelle di Tomaso; Carla Mouta Carreira; Edward B Brown; Yves Boucher; Noah C Choi; Douglas Mathisen; John Wain; Eugene J Mark; Lance L Munn; Rakesh K Jain
Journal:  Science       Date:  2002-04-25       Impact factor: 47.728

6.  Independent prognostic impact of lymphatic vessel density and presence of low-grade lymphangiogenesis in cutaneous melanoma.

Authors:  Oddbjørn Straume; David G Jackson; Lars A Akslen
Journal:  Clin Cancer Res       Date:  2003-01       Impact factor: 12.531

7.  Prognostic value of lymph node dissection in patients with muscle-invasive transitional cell carcinoma of the upper urinary tract.

Authors:  Marco Roscigno; Cesare Cozzarini; Roberto Bertini; Vincenzo Scattoni; Massimo Freschi; Luigi Filippo Da Pozzo; Alberto Briganti; Andrea Gallina; Umberto Capitanio; Renzo Colombo; Guazzoni Giorgio; Francesco Montorsi; Patrizio Rigatti
Journal:  Eur Urol       Date:  2008-01-15       Impact factor: 20.096

8.  Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial.

Authors:  Peter Albers; Roswitha Siener; Sabine Kliesch; Lothar Weissbach; Susanne Krege; Christoph Sparwasser; Harald Schulze; Axel Heidenreich; Werner de Riese; Volker Loy; Erhard Bierhoff; Christian Wittekind; Rolf Fimmers; Michael Hartmann
Journal:  J Clin Oncol       Date:  2003-04-15       Impact factor: 44.544

9.  The impact of tumor location on prognosis of transitional cell carcinoma of the upper urinary tract.

Authors:  Sungchan Park; Bumsik Hong; Choung-Soo Kim; Hanjong Ahn
Journal:  J Urol       Date:  2004-02       Impact factor: 7.450

10.  Early postoperative peripheral blood reverse transcription PCR assay for prostate-specific antigen is associated with prostate cancer progression in patients undergoing radical prostatectomy.

Authors:  Shahrokh F Shariat; Michael W Kattan; Weitao Song; David Bernard; Emanuel Gottenger; Thomas M Wheeler; Kevin M Slawin
Journal:  Cancer Res       Date:  2003-09-15       Impact factor: 12.701

View more
  77 in total

1.  [Detection of lymphovascular invasion in urothelial carcinoma of the bladder through D2-40 immunostaining].

Authors:  T Martini; P Ströbel; A Steidler; N Petrakopoulou; P Erben; C Bolenz
Journal:  Urologe A       Date:  2015-01       Impact factor: 0.639

2.  Combining imaging and ureteroscopy variables in a preoperative multivariable model for prediction of muscle-invasive and non-organ confined disease in patients with upper tract urothelial carcinoma.

Authors:  Ricardo L Favaretto; Shahrokh F Shariat; Caroline Savage; Guilherme Godoy; Daher C Chade; Matthew Kaag; Bernard H Bochner; Jonathan Coleman; Guido Dalbagni
Journal:  BJU Int       Date:  2011-06-01       Impact factor: 5.588

3.  [Urothelial carcinoma of the upper urinary tract: clinical and pathological criteria and their predictive implications after radical nephroureterectomy].

Authors:  Christian Seitz; Paul Schramek
Journal:  Wien Med Wochenschr       Date:  2011-08

Review 4.  [Upper tract urothelial carcinoma. An update on clinical and pathological prognostic factors].

Authors:  M Rink; M Adam; J Hansen; F K Chun; S A Ahyai; M Remzi; T Schlomm; O Engel; R Heuer; C Eichelberg; M Fisch; R Dahlem; S F Shariat
Journal:  Urologe A       Date:  2012-09       Impact factor: 0.639

5.  Risk stratification of metastatic recurrence in invasive upper urinary tract carcinoma after radical nephroureterectomy without lymphadenectomy.

Authors:  Pierre Colin; Tarek P Ghoneim; Laurent Nison; Thomas Seisen; Eric Lechevallier; Xavier Cathelineau; Adil Ouzzane; Marc Zerbib; Jean-Alexandre Long; Alain Ruffion; Sébastien Crouzet; Olivier Cussenot; Marie Audouin; Jacques Irani; Solène Gardic; Pascal Gres; François Audenet; Mathieu Roumiguié; Antoine Valeri; Morgan Rouprêt
Journal:  World J Urol       Date:  2013-06-29       Impact factor: 4.226

6.  Urothelial carcinomas of the upper urinary tract are now recognised as a true and distinct entity from bladder cancer and belong fully to the broad spectrum of onco-urologic neoplasms.

Authors:  Morgan Rouprêt; Pierre Colin
Journal:  World J Urol       Date:  2012-09-27       Impact factor: 4.226

7.  Prognostic importance of lymphovascular invasion in urothelial carcinoma of the renal pelvis.

Authors:  Matthew R Danzig; Katherine Mallin; James M McKiernan; Walter M Stadler; Srikala S Sridhar; Todd M Morgan; Bernard H Bochner; Cheryl T Lee
Journal:  Cancer       Date:  2018-04-06       Impact factor: 6.860

8.  Upper urinary tract urothelial carcinoma: what have we learned in the last 4 years?

Authors:  Mesut Remzi; Shahrokh Shariat; Wilhelm Huebner; Harun Fajkovic; Christian Seitz
Journal:  Ther Adv Urol       Date:  2011-04

Review 9.  Prognostic factors and predictive tools for upper tract urothelial carcinoma: a systematic review.

Authors:  Aurélie Mbeutcha; Morgan Rouprêt; Ashish M Kamat; Pierre I Karakiewicz; Nathan Lawrentschuk; Giacomo Novara; Jay D Raman; Christian Seitz; Evanguelos Xylinas; Shahrokh F Shariat
Journal:  World J Urol       Date:  2016-04-21       Impact factor: 4.226

Review 10.  Prognostic factors for upper urinary tract urothelial carcinoma.

Authors:  Thomas F Chromecki; Karim Bensalah; Mesut Remzi; Grégory Verhoest; Eugene K Cha; Douglas S Scherr; Giacomo Novara; Pierre I Karakiewicz; Shahrokh F Shariat
Journal:  Nat Rev Urol       Date:  2011-07-05       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.